The Autologous Cell Therapy Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The market size for autologous cell therapy has been expanding swiftly in the past years. The market, which was valued at $10.28 billion in 2024, is predicted to reach $12.19 billion in 2025, growing at a CAGR of 18.6%.
The Autologous Cell Therapy Global Market is predicted to reach a size of $23.33 billion in 2029, growing at a compound annual growth rate (CAGR) of 17.6%.
Download Your Free Sample of the 2025 Autologous Cell Therapy Market Report and Uncover Key Trends Now!The key drivers in the autologous cell therapy market are:
• Continued growth and advancements in regenerative medicine
• Diversification of applications across various medical specialties
• Development of advanced cell culture techniques
• Increased investment and research initiatives along with regulatory support and standardization
The autologous cell therapy market covered in this report is segmented –
1) By Therapy: Autologous Stem Cell Therapy, Autologous Cellular Immunotherapies
2) By Source: Bone Marrow, Epidermis, Mesenchymal Stem Cells, Hematopoietic Stem Cells, Chondrocytes, Other Sources
3) By Application: Cancer, Neurodegenerative Disorders, Cardiovascular Disorders, Autoimmune Disorders, Orthopedics, Wound Healing, Other Applications
4) By End User: Hospitals And Clinics, Ambulatory Centers, Academics And Research, Other End-Users
The key trends in the autologous cell therapy market are:
• Development of automated manufacturing technologies is a major upcoming trend.
• The integration of biomarkers in treatment strategies is emerging as a key influence.
• The future is expected to see an emergence of point-of-care cell processing.
• Industry collaboration and partnerships are becoming increasingly prevalent.
The major players in the autologous cell therapy market are:
• Bristol Myers Squibb Company
• Novartis AG
• Vericel Corporation
• Holostem Terapie Avanzate S
North America was the largest region in the autologous cell therapy market in 2024